Home >> Top News >> Thermo Fisher to sell anatomic pathology business

Thermo Fisher to sell anatomic pathology business

Print Friendly, PDF & Email

Feb. 4, 2019—Thermo Fisher Scientific announced it has signed a definitive agreement to sell its anatomical pathology business to PHC Holdings Corp. for approximately $1.14 billion. The company’s AP business is a provider of microscope slides, instruments, and consumables and employs approximately 1,200 people in the United States, Europe, and China. PHC Holdings develops, manufactures, sells, and services medical equipment and solutions for the diabetes care, diagnostics, life sciences, and health care IT industries.

The transaction is expected to close in the second quarter of this year.


Check Also

CMS extends coverage of Oncomine Dx test, 5/18

May 2018—Thermo Fisher Scientific announced its Oncomine Dx Target Test has been approved for coverage by the Centers for Medicare and Medicaid Services as part of the agency’s national coverage determination for next-generation sequencing in vitro diagnostic tests.